African-Americans with Hypertensive CKD overview
Chronic Kidney Disease (CKD), the progressive loss of kidney function, disproportionally impacts African-Americans, which are three to four times more likely to suffer from CKD than Caucasians. One of the most severe consequences of untreated CKD is an end-stage renal disease (ESRD), where the kidneys have ceased to function, and the individual requires continuous on-going dialysis or kidney transplantation.
Who takes part in the study?
Florida Kidney Physicians in collaboration with Elixia Clinical Research is looking for African Americans patients who suffer from CKD, have high blood pressure and are non-diabetic located in South Florida, Tampa Bay Area or Philadelphia.
What are the benefits?
You will be paid for your time and participation in this study, $2,400 compensation plus the medication and transportation if they are needed. Because of COVID-19, after the first visit, the nurse goes to the patient’s house.
About the African Americans – Hypertensive with CKD
DM199 was created as a protein replacement therapy. In the case of non-diabetic, hypertensive African Americans with CKD, we believe that DM199 represents a potential shift in the treatment paradigm. We believe that DM199 may potentially act on the following inter-related mechanisms in the kidney to promote better overall function, stable blood flow, and ultimately may potentially protect the kidney from further damage.
What to expect
The study is designed to evaluate changes in eGFR (blood flow through the kidney) and protein albuminuria (renal filtration ability). Elixia Clinical Research also intends to identify subjects with the APOL1 risk allele(s) to assess its impact on response to DM199 therapy.
How to apply?